Caris Life Sciences, Inc. Reports Results of 2026 Annual Meeting of Shareholders
Caris Life Sciences, Inc. (NASDAQ: CAI) has announced the results of its 2026 Annual Meeting of Shareholders, held on June 4, 2026. The meeting addressed two significant proposals that are important for investors to note, as both could influence the company’s strategic direction and, potentially, its share value.
Key Points and Shareholder Actions
- Election of Directors: All ten nominees for the Board of Directors were elected to serve until the 2027 Annual Meeting of Shareholders, or until their successors are duly elected and qualified, or their earlier death, resignation, disqualification, or removal.
- Ratification of Independent Auditor: Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Strong Shareholder Participation: Out of 282,662,545 shares of common stock issued and outstanding as of the April 9, 2026 record date, 273,714,520 shares were represented at the meeting, constituting a quorum.
Detailed Voting Results
1. Election of Directors
The following ten directors were elected. Notably, substantial “Votes Withheld” were recorded for some directors, which investors may interpret as an indicator of shareholder sentiment.
| Name | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| David Dean Halbert | 46,829,215 | 11,087,026 | — |
| Jon S. Halbert | 215,600,787 | 47,026,707 | 11,087,026 |
| Laura I. Johansen | — | — | — |
| Dr. Jeffrey Vacirca | 228,673,484 | 33,954,010 | 11,087,026 |
Note: Votes for some directors (e.g., Jon S. Halbert and Dr. Jeffrey Vacirca) were overwhelmingly positive, but the number of votes withheld suggests some shareholders may have concerns or desire changes in board composition.
2. Ratification of Deloitte & Touche LLP as Independent Auditors
| Votes For | Votes Against | Abstain |
|---|---|---|
| 273,517,324 | 60,882 | 136,314 |
This near-unanimous approval signals strong shareholder confidence in the company’s financial oversight and continued relationship with Deloitte & Touche LLP.
Other Important Information for Shareholders
- Emerging Growth Company Status: Caris Life Sciences, Inc. continues to qualify as an “emerging growth company” under SEC rules.
- Corporate Details: The company is incorporated in Texas and is listed on the NASDAQ under the ticker symbol “CAI”.
- No Other Price-Sensitive Proposals: No other matters were brought to vote that would be considered price sensitive or likely to affect share value in the immediate term.
Potential Impact on Share Value
While the election of directors and ratification of auditors are routine matters for most public companies, the relatively high number of votes withheld from certain directors may be noteworthy for investors monitoring governance trends and potential activist involvement. Strong support for Deloitte & Touche LLP as auditors supports ongoing confidence in the company’s financial reporting.
Executive Sign-Off
This 8-K report was signed by Luke Power, Senior Vice President, Chief Financial Officer, and Chief Accounting Officer, on behalf of Caris Life Sciences, Inc. on June 5, 2026.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult with their financial advisors and review the full SEC filings and company disclosures before making investment decisions. The author and publisher assume no responsibility or liability for any actions taken based upon the information contained herein.
